- Home
- LFVN vs TCRX Comparison
LFVN vs TCRX Comparison
Compare LFVN & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | TCRX |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.9M | 63.6M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFVN | TCRX |
|---|---|---|
| Price | $4.19 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 78.0K | ★ 572.9K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ 226.09 | 12.28 |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $203,204,000.00 | $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $22.37 | ★ N/A |
| Revenue Growth | 1.86 | ★ 266.65 |
| 52 Week Low | $3.90 | $0.88 |
| 52 Week High | $15.37 | $2.57 |
Technical Indicators
Market Signals| Indicator | LFVN | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 45.51 |
| Support Level | $3.99 | $0.99 |
| Resistance Level | $5.37 | $1.24 |
| Average True Range (ATR) | 0.25 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 14.12 | 40.91 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.